Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM88 in Patients With Prostate Cancer
NCT02796898Phase 2Completed
- Sponsor
- Tyme Technologies
- Start
- Jun 2016
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of racemetyrosine in prostate cancer (PCa) (3 cohorts), sponsored by Tyme Technologies. Primary endpoints: Dose Limiting Toxicity at 6 months and Maximum Tolerated Dose at 6 months. Started Jun 2016; status: completed.
02
Drugs
racemetyrosine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02796898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02796898.